Skip to content
Home/Companies/Biotech/Flamingo Therapeutics

Flamingo Therapeutics

Biotech·France·Active·8yr hold
Entry
2018
Hold
8yr
Status
Active

Who owns Flamingo Therapeutics?

Flamingo Therapeutics is a French Biotech company, currently owned by Andera Partners since 2018.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Andera Partners
Investor
Andera Partners
BioDiscovery 5 · 2017 · VC

Key facts

HQFrance
SectorBiotech

More from BioDiscovery 5

Other portfolio companies in the same fund.

Amolyt Pharma
Amolyt Pharma
Exited 2024
BiotechFrance· 2021
to AstraZeneca
Evommune
Evommune
Exited 2025
BiotechFrance· 2021
to Public market (NYSE IPO ticker EVMN)
Nyxoah
Nyxoah
Active
MedTechBelgium· 2020
AgoMab
AgoMab
Exited 2026
BiotechFrance· 2019
to Public market (Nasdaq IPO ticker AGMB)
AM Pharma
AM Pharma
Active
BiotechNetherlands· 2019
Arvelle
Exited 2021
BiotechSwitzerland· 2019
to Angelini Pharma

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Flamingo Therapeutics?

Flamingo Therapeutics is currently owned by Andera Partners, through BioDiscovery 5, since 2018.

When did Andera Partners acquire Flamingo Therapeutics?

Andera Partners acquired Flamingo Therapeutics in 2018.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue